Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for LifeStance Health (LFST) over the last 5 years, with FY2024 value amounting to -$9.9 million.

  • LifeStance Health's Cash from Financing Activities rose 14.81% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.0 million, marking a year-over-year decrease of 18873.66%. This contributed to the annual value of -$9.9 million for FY2024, which is 12097.33% down from last year.
  • Per LifeStance Health's latest filing, its Cash from Financing Activities stood at -$9.9 million for FY2024, which was down 12097.33% from $47.4 million recorded in FY2023.
  • LifeStance Health's 5-year Cash from Financing Activities high stood at $313.9 million for FY2021, and its period low was -$9.9 million during FY2024.
  • Over the past 4 years, LifeStance Health's median Cash from Financing Activities value was $47.3 million (recorded in 2022), while the average stood at $99.6 million.
  • Per our database at Business Quant, LifeStance Health's Cash from Financing Activities skyrocketed by 34.49% in 2023 and then crashed by 12097.33% in 2024.
  • Annual analysis of 4 years shows LifeStance Health's Cash from Financing Activities stood at $313.9 million in 2021, then tumbled by 84.94% to $47.3 million in 2022, then rose by 0.34% to $47.4 million in 2023, then crashed by 120.97% to -$9.9 million in 2024.
  • Its Cash from Financing Activities stands at -$9.9 million for FY2024, versus $47.4 million for FY2023 and $47.3 million for FY2022.